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Loss of bone mineral density due to osteoporosis is the main cause of fragility fractures and leads to dropped
quality of life and increased mortality. Disturbance of balance between bone formation and bone resorption is
dangerous, can cause loss of bone mass and disruption of it’s architecture. Correct development, achievement of
peak bone mass and normal functioning of human skeleton depend on different factors. The pivotal role in bone
metabolism play thyroid hormones. Both excess as well as deficiency of fT4 and fT3 can be potentially deleterious
for bone tissue.
The aim of this study is to review the current literature concerning the role of thyroid hormones on bone metabolism.
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A lot of different factors are necessary to correct and
harmonious development as well as normal functioning
of skeleton: genetic conditions, hormonal and metabolic
homeostasis, balanced diet, mechanical load [1]. Any
disturbances of those agents can lead to serious and
dangerous consequences like length reduction, deforma-
tions, fractures. Their results depend, between other, on
one’s age, type of disorder and its duration. We don’t
have any influence on some of mentioned before factors,
but part from them is possible to modify. It is very sig-
nificant because abnormalities and irregularities of bone
mineralization can lead to loss of bone density and to
osteoporosis in final effect [1].
Because of rising number of newly diagnosed osteo-
porosis cases it is necessary to perform an active investi-
gation for all potential secondary conditions which can
lead to reduced bone mineral density. It is very import-
ant because osteoporotic fractures are directly related
with dropped quality of life, disability and mortality. It is
estimated that 40% of women and 13-22% of men aged
about 50 will experience to the end of life at least one
fracture connected with osteoporosis – mainly proximal
femur, spine or forearm [2]. Society’s aging causes that* Correspondence: dominess@wp.pl
1Endocrinology Department, Clinic of Internal Medicine, 4th Military Hospital,
Wrocław, Poland
Full list of author information is available at the end of the article
© 2014 Tuchendler and Bolanowski; licensee B
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.the number of people with osteoporotic fracture in
Poland will amount in year 2025 about 3.23 millions. It
means growth about 32.8% relatively to year 2008. Be-
sides, unfortunately a trend appeared that osteoporosis,
mainly secondary, is diagnosed in more and more youn-
ger age groups.
There is a lot of endocrinological reasons of secondary
osteoporosis (for example: Cushing's syndrome, hyper-
parathyroidism, hypogonadism, acromegaly, diabetes mel-
litus etc.) [3]. It is necessary to remember about them
because their negative influence on bone tissue is poten-
tially reversible. In this group also thyroid gland hormonal
disorders play an important role. Human interest about
the influence of thyroid hormone on skeleton lasts since
long time. Von Recklinghausen described a correlation be-
tween numerous fractures and state of hyperthyroidism
over 120 years ago [4]. Researches and discussions persist
if the key role on bone tissue has TSH or thyroid hor-
mones? Is this question important? The answer is yes, be-
cause disorders of thyroid gland and disturbances of axis
TRH-TSH-fT3 and fT4 are very often; concern millions of
people in global scale. The implications for bone leading
to bone loss causes that willingness of the answer to the
question about the influence of thyroid dysfunction on
bone is quite great.ioMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Molecular actions of thyroid hormones in bone tissue
The action of thyroid hormones is mediated by thyroid
hormone receptors (TR), which are encoded by THRA
and THRB genes [4]. Each of TR owns a few subtypes.
We can differ TRα1, TRα2, TRβ1, TRβ2 receptors [5-7].
They are localized not only on thyrocytes, but also on
majority human tissues and cells. Only TRβ2 is con-
nected with hypothalamus and pituitary, where inhibits
the secretion of TRH and TSH [8,9]. Their expression in
bone directly means that this tissue is under the influ-
ence of thyroid hormones. Osteoblasts and chondrocytes
exert the expression of both TRα and TRβ [5,6,10], but
concentration of TRα1 is ten times larger than TRβ1
[4,5]. TRα1 is considered as a main functional mediator
of triiodothyronine in skeleton [5,11,12]. The biological
role of TRα2 is unknown [13]. Deficiency or dysfunction
of TRα leads to growth retardation, delayed bone age, per-
turbations in bone mineralisation and decreased BMD
[8,14]. T3 regulates the chondrogenesis and bone mineral-
isation [6]. T3 stimulates the IL-6 and IL-8, intensifies the
effects of IL-1 and IL-6, augments the synthesis of osteo-
calcin, collagen type 1, increases proliferation, differenti-
ation and apoptosis of osteoblasts [8].
The receptors for TSH (TSHR) are located not only in
thyroid follicular cells, but also in osteoblasts and osteo-
clasts [4,5]. Data from scientific reports indicates that
TSH is considered as a negative regulator of bone turn-
over [4]. Its direct action on bone tissue cells leads to
enhanced bone remodeling and osteoporosis [15,16].
The influence of overt hyperthyroidism on bone
Thyroid hormones play pivotal role in linear develop-
ment of skeleton. They are necessary to achieve peak
bone mass [8]. But the excess of thyroid hormones in
childhood can lead to premature accretion of growth
plates and cranial sutures and finally short stature and
craniosynostosis [8,13,17,19]. In adults, overt hyperthy-
roidism leads to acceleration of bone turnover and loss
of mineral density in 10-20%, mainly in cortical bone
[8,13,19]. The cycle of bone remodeling is shortened in
almost 50% (from 200 to 113 days), and the proportions
between bone formation and bone resorption are dis-
turbed [20]. The phase of bone formation is reduced in
2/3, which effects in loss of over 10% mineralized bone
on one cycle [21]. In consequence thyrotoxicosis leads
to increased risk of fractures [8,13,20,22]. Elevated
serum concentrations of IL-6 are observed in people
with hyperthyroidism [23,24]. IL-6 stimulates the pro-
duction of osteoclasts and may be a mediator of parathy-
roid hormone on bone tissue [23,24]. Adverse changes in
bone metabolism seen in hyperthyroidism are connected
with negative calcium balance, hypercalcaemia and hyper-
calciuria [13,23].Since times of von Recklinghausen many authors
returned in their researches to the topic of thyroid gland
hormonal dysfunction and its influence on skeleton (18).
Svare et al. in cross-sectional, population-based study
HUNT 2 in Norway exerted that women with lowest TSH
concentrations (<0.5 m U/l) had lower forearm BMD than
reference category. In this research also the prevalence of
osteoporosis was higher in women with history of hyper-
thyroidism [25]. Vestergaard et al. in a meta-analysis from
year 2003 noted that BMD was significantly decreased in
patients with untreated hyperthyroidism. During anti-
thyroid treatment a statistically significant increase in
BMD was observed and it reversed to initial normal levels
with even temporary increase above normal levels within
1 to 4 years after diagnosis. The risk of hip fractures was
correlated positively with age at time of diagnosis of
hyperthyroidism [26]. Ercolano et al. examined 57 women
with diagnosed Graves’ disease, who were in state of
euthyroidism (for minimum 6 months) during study, but
with previous history of hyperthyroidism and wanted to
determine the correlation with BMD and TSH receptor
antibodies (TRAb). They concluded that BMD was de-
creased only in postmenopausal women and they found a
negative correlation between Z-score of lumbar spine and
TRAb [27]. Tuchendler et al. in their study on 38 premen-
opausal women with newly diagnosed hyperthyroidism
noted that a decrease in bone mineral density occurred in
cortical bone (femoral neck). After one year of anti-
thyroid treatment an increase in BMD was observed, but
it was still lower that in control group, which indicated
that correcting the hormonal dysfunction didn’t fully
normalize bone density. The negative impact on bone
equilibrium expressed first as an increase in markers of
bone turnover. This observation permitted detection of
bone loss at an earlier stage preceding changes observed
in X-ray densitometry. After one year of anti-thyroid treat-
ment concentrations of bone turnover markers decreased
in a statistically significant way [28]. El Hadidy et al. found
out that not only women, but also men suffering from
hyperthyroidism (Graves’ disease or multinodular toxic
goiter) had significant bone loss and it was related with
the severity and duration of thyrotoxic state [29].
Not only current thyrotoxicosis is a risk factor of fra-
gility fracture, but also previous history of hyperthyroid-
ism belongs to independent risk factors for hip and
vertebral fractures. Wejda et al. described that hyperthy-
roidism was found 2.5-fold more often in hip fracture
patients than in controls [30]. Bauer et al. noted that
postmenopausal women with decreased TSH concentra-
tions (<0.1 mU/L) had a threefold increased risk for hip
and a fourfold increased risk for vertebral fracture com-
pared with women with normal TSH levels (from 0.5 to
5.5 mU/L). There was an interesting detail that a history
of hyperthyroidism was also associated with a twofold
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BMD doesn’t return to normal ranges after anti-thyroid
treatment.
Vestergaard et al. in their case–control study in the
year 2000 in Denmark noticed an increase in the risk of
any fracture within the first 5 years after a diagnosis of
hyperthyroidism. Use of anti-thyroid drugs was associ-
ated with a significantly reduced fracture risk independ-
ently of the dose used [32]. In this aspect another study
of the same author was very interesting because he ob-
served an increased fracture risk in hyperthyroidism
treated with radioactive iodine alone, but not in subjects
that had received both radioactive iodine and methima-
zole or other types of anti-thyroid therapy. His study
considered of 864 patients with diffuse toxic goiter or
toxic nodular goiter [33].
The influence of subclinical hyperthyroidism on bone
We have very little data from medical studies describing
the influence of subclinical hyperthyroidism on bone
metabolism. It is an object of discussion, still. Lee et al.
concluded that women having subclinical hyperthyroidism
had reduced femoral neck BMD but not lumbar spine
BMD. Serum concentration of bone turnover markers
showed no differences between studied and control group
[34]. Folder et al. in his cross-sectional study indicated that
the bone mineral density of the lumbar spine, femoral
neck and the midshaft of the radius were not significantly
decreased in premenopausal patients with endogenous
subclinical hyperthyroidism but he also concluded that
long-lasting endogenous subclinical hyperthyroidism may
be a contributing factor to the development of osteopor-
osis in some postmenopausal women, mostly at sites
where cortical bone preponderates [35]. Vadiveloo et al.
wanted to investigate the long-term outcomes, between
other fracture risk, for patients with endogenous subclin-
ical hyperthyroidism (SH). They concluded that patients
with endogenous SH have an increased risk of fracture
with a hazard ratio 1.25, but when they developed overt
hyperthyroidism or euthyroidism and were excluded from
the study, this association was lost [36]. Lee et al. con-
cluded that older men (>65 years old) with subclinical
hyperthyroidism were at increased risk for hip fracture.
No clear association between subclinical dysfunction and
fracture was observed in women in this study [37].
The situation is complicated with reference to premeno-
pausal women. Ugur-Altun et al. didn’t find any difference
in BMD between group of premenopausal women with
untreated subclinical hyperthyroid in the course of Graves’
disease (age 33 ± 5 years) and healthy women (age 35 ±
3 years) [38]. Tauchmanovà et al. examined the group of
60 patients with endogenous subclinical hyperthyroidism
due to multinodular goiter: 30 of women were premeno-
pausal and 30 early postmenopausal (mean age, 40.9 ± 7.3and 57.7 ± 6.75, respectively). She observed a significant
decrease in femoral BMD both in pre- and postmeno-
pausal patients compared to controls (but being greater in
those postmenopausal). Also lumbar BMD was decreased
but only in postmenopausal patients [39]. Rosario noticed
a significant increase in serum markers of bone formation
and resorption in premenopausal women with subclinical
hyperthyroidism aged < 65 years. In his research bone
mineral density was lower in the femoral neck but not in
lumbar spine in patients before menopause, whereas lower
BMD at both sites was observed in postmenopausal pa-
tients [40].
The influence of overt hypothyroidism on bone
Untreated hypothyroidism in childhood leads to growth
retardation or even growth arrest, disturbances of endo-
chondral ossification, delayed bone age and persistent
short stature [8,13,19]. Hypothyroidism causes general
hypometabolism [20]. Bone formation processes are slo-
wed in 50%, bone resorption processes – in 40% [20].
The calciuria is reduced, serum concentration of osteo-
calcin and alkaline phosphatase is decreased, but serum
concentration of parathyroid hormone and vitamin D
can be elevated [20]. The influence of deficiency of thy-
roid hormones on bone metabolism is discussed. Never-
theless, it is considered that hypothyroidism is related
with increased risk of fractures, although their mechan-
ism remains unclear [9]. Hanna et al. noted that there
was no evidence for a difference in bone mineral density
in patients receiving replacement doses of thyroxine ir-
respective of the etiology of hypothyroidism [41]. Leger
et at proved that LT4 replacement therapy among chil-
dren with congenital hypothyroidism is not detrimental
to the skeletal mineralization [42].
Vestergaard et al. noted that there was a temporary
increase in fracture risk within the first 2 years after
diagnosis of primary idiopathic hypothyroidism. The
fracture risk was mainly increased in the age group
above 50 years, and the increased risk was limited to the
forearms [43]. In another study of the same author was
noticed that there was an increase in the risk of any
fracture within the first 10 years after a diagnosis of
hypothyroidism. No effect of levothyroxine on fracture
risk was present in that research [32]. Gonzalez-Rodriguez
et al. did not find any association between hypothyroidism
and decreased bone mineral density or vertebral and non-
vertebral fractures among 400 women suffering from
hypothyroidism [44]. Lee et al. concluded that men over
65 years old with subclinical hypothyroidism were at in-
creased risk for hip fracture. Whether treatment of the
subclinical syndrome reduced this risk was unknown [38].
Polovina et al. noticed that postmenopausal patients with
subclinical hypothyroidism, in particular of autoimmune
origin, have higher FRAX scores and a thus greater risk for
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women [45]. Tuchendler et al. noted that newly diag-
nosed hypothyroidism among premenopausal women
(average age 33,37 ± 10,83) did not have an influence on
bone density [28].
The influence of suppressive doses of levothyroxine
on bone
Suppressive doses of L-T4 are used in patients with differ-
entiated thyroid carcinoma as a complementary treatment
after thyroidectomy and radioactive iodine therapy. Al-
though an endogenous hyperthyroidism is a risk factor of
secondary osteoporosis, the effects supraphysiological
doses of levothyroxine on bone are still under discussion.
Heemstra et al. suggested that in postmenopausal women
after long-term suppressive thyroxine replacement therapy
decreased BMD and increased risk of osteoporosis was ob-
served, whereas it wasn’t noted among men and premeno-
pausal women [46]. Quan et al. analyzed 11 researches
concerning the effects of suppressive thyroxine therapy in
patients with well-differentiated thyroid cancer on bone
metabolism. They didn’t notice significant change in bone
mineral density among premenopausal women and men.
Findings for postmenopausal women remained unclear
and needed further studies [47].
Lee et al. observed 94 females (mean age, 50.84 ±
11.43 years) receiving L-T4 after total or near total thy-
roidectomy and radioactive iodine therapy for thyroid can-
cer. They detected no significant decrease in BMD or
bone turnover markers according to TSH level or free T4
level. Also, the prevalence of osteoporosis and osteopenia
was not increased in this study [48]. Franklyn et al. con-
cluded that despite long-term thyroxine therapy (mean
duration 7.9 [range 1–19] years) which resulted in higher
serum thyroxine and lower serum TSH concentrations
than in the controls, the patients showed no evidence of
lower bone mineral density than the controls at any site.
There was a decrease in bone density with age in both
groups. They suggested that thyroxine alone didn’t have a
significant effect on bone mineral density and hence on
risk of osteoporotic fractures [49].
Kung et al. observed for 2 years 46 postmenopausal
women with carcinoma of thyroid gland to evaluate the
rate of bone loss. All patients were receiving a stable dose
of L-T4 (170 ± 60 micrograms/day or 3.0 ± 1.4 micro-
grams/kilogram/day) for more than 1 year. They noticed
that T4-suppressive therapy was associated with bone loss
in postmenopausal women [50]. Uzzan et al. performed a
meta-analysis (by pooling standardized differences, using a
fixed effect model) of all published controlled cross-
sectional studies (41, including about 1250 patients) con-
cerning the impact of thyroid hormones therapy on bone
mineral density. They found out that for lumbar spine and
hip (as for all other sites), suppressive thyroid hormonestherapy was associated with significant bone loss in
postmenopausal women but not in premenopausal
women [51].
There is no data in literature evaluating the fracture
risk and the concentrations of bone turnover markers in
premenopausal women treated with suppressive doses
of levothyroxine by the reason of differentiated thyroid
carcinoma.
Conclusions
Thyroid hormones are necessary to normal development
and function of human skeleton. This is evidently visible
in conditions of hyper- and hypothyroidism. Although it is
still unclear if bone changes observed in state of thyrotoxi-
cosis are related to lack of TSH or to excess of thyroid
hormones or both of them. Overt hyperthyroidism leads
to decreased BMD and increased fracture risk. Subclinical
hyperthyroidism also causes a small reduction in BMD
and increased risk of fracture but only in men ant post-
menopausal women. Then suppressive doses of T4 can
contribute to reduced BMD due to patient’s sex and gen-
der (in postmenopausal females). Hypothyroidism has
controversial influence on bone metabolism but probably
leads to increased fracture risk.
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